Stockholders Approve Aggressive Reverse Split to Address Nasdaq Compliance

summarizeSummary

Stockholders approved a highly aggressive reverse stock split (up to 1-for-100) to help Quince Therapeutics maintain its Nasdaq listing, following previous compliance issues and a recent 1-for-10 split.

check_boxKey Events

• Reverse Stock Split Authorized

  Stockholders approved an amendment to the certificate of incorporation, authorizing the board to effect a reverse stock split at a ratio ranging from 1-for-10 to 1-for-100. This follows previous efforts to address Nasdaq's minimum bid price requirement.

• Director Elected

  June Bray was elected as a Class I director to the Board of Directors, serving until the 2029 annual meeting.

• Auditor Ratified

  BDO USA, P.C. was ratified as the independent registered accounting firm for the fiscal year ending December 31, 2026.

auto_awesomeAnalysis

Quince Therapeutics' stockholders have authorized the board to implement a reverse stock split at a ratio of up to 1-for-100. This is a critical step for the micro-cap company, which has a history of Nasdaq non-compliance and previously executed a 1-for-10 reverse split in April 2026. The approval provides the company with the necessary flexibility to potentially increase its share price and meet Nasdaq's minimum bid price requirement, thereby avoiding delisting. While necessary for survival, the need for such a drastic measure underscores the company's ongoing challenges.